

2026 Eligible Drug List

Proposed Drug Aggregation
Methodology

Background

- ▶ The Prescription Drug Affordability Board is tasked with creating a list of drugs that are eligible for affordability review, according to parameters laid out in Chapter 70.405 RCW.
- ▶ There are options in how to compile the list of drugs eligible for an affordability review.
 - ▶ One approach is to aggregate drugs by ingredient and by labeler.
 - ▶ A second approach is to compile the list solely by drug ingredient, thereby grouping multiple manufacturers under each “drug.”

Current Drug List

- ▶ Drugs are aggregated by ingredient *and* labeler.
- ▶ Aggregating by both ingredient and labeler separates drug products with identical drug ingredients when they are manufactured by different entities.
- ▶ This means in any PDAB drug list and subsequent analysis, the costs ascribed to the drug ingredient (e.g. Drug Ingredient Alpha) will be split across multiple drug products.
 - ▶ e.g. Drug Product 1 from Manufacturer A, Drug Product 2 from Manufacturer B, and Drug Product 3 from Manufacturer C would show at 3 individual costs rather than as a single, total value for the drug ingredient
- ▶ This potentially makes the drug appear to have a smaller overall cost and utilization than if all costs were ascribed to one drug ingredient.
 - ▶ e.g. all sales from Drug Product 1, 2, and 3 were ascribed to “Drug Ingredient Alpha” in the PDAB list.

Current Drug List

| Drug Product | Claims | Cost |
|----------------|--------|----------|
| Drug Product 1 | 1,000 | \$10,000 |
| Drug Product 2 | 2,000 | \$15,000 |
| Drug Product 3 | 500 | \$5,000 |
| Drug Total | 3,500 | \$30,000 |

| Drug Ingredient | Claims | Cost |
|-----------------------|--------|----------|
| Drug Ingredient Alpha | 3,500 | \$30,000 |

Proposed Approach for 2026

- ▶ An alternate approach is to consider the manufacturer when the initial list is created.
 - ▶ e.g. determine drug eligibility based on ingredient and labeler.
- ▶ Then aggregate at the ingredient level when selecting drugs for the affordability review.
- ▶ This would ensure that all drugs under review meet the statutory requirements placed based on labeler type.
- ▶ And that drugs would be selected for review based on the cumulative impact of all drug products with the same drug ingredient in the Washington market.
- ▶ PDAB would then add a section to the Drug Data Dashboard with a list of drugs aggregated at the ingredient level.



Questions?
